Mymetics Corporation (OTCQB: MYMX). We develop next-generation of prophylactic vaccines for infectious and life disabling diseases based on virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins and specifically designed antigens.
Products, services, technology
World leading experts in R&D of enveloped virus like particle vaccines based on our virosome vaccine platform. Platform allows incorporation of peptides, recombinant proteins and natural viral proteins together with adjuvant, if required, all on one particle for intranasal and im administration.
Collaboration possible in cancer immunotherapy either in combination with check point blockade or enhancing the response rates of existing cancer antigens by using our safe, proven, GMP ready proprietary virosome based vaccine platform (known for specific CD8+ and CD4+ Tcell increase)